FLGT News and Press, Fulgent Genetics Inc. From 02/23/22

Fulgent Genetics (NASDAQ:FLGT) announced a strategic investment in Spatial Genomics, a developer of sequential fluorescence in situ hybridization (seqFISH) technology. FLGT is investing up to $40M to lead Spatial's series A financing, which totals ~$56M and also includes investments by 12 Wes...

Fulgent Genetics press release (NASDAQ:FLGT): Q4 Non-GAAP EPS of $3.48 beats by $0.81. Revenue of $251.7M beats by $60.6M. Shares -5%. Outlook Q1 2022:T otal Revenue of approximately $245 million; Core Revenue including COVID-19 NGS of approximately $32 million, representing growth ...

Strategic investment and partnership brings Spatial’s multiomics platform and seqFISH technology to Fulgent’s comprehensive suite of genomic testing solutions Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a tech...

Full Year 2021 Total Revenue grows 135% year-over-year to $992.6 million; Q4 Revenue totals $251.7 million Full Year 2021 Core Revenue grows 236% year-over-year to $122.6 million; Q4 Core Revenue grows 234% year-over-year to $40.1 million Fulgent Genetics, Inc. (NASDAQ: ...

AAN, ACA, OTCPK:ACLLF, AEM, AEVA, AGI, AHT, ALLO, ALR, AMED, ANSS, ARNA, AZUL, BAND, BBDC, BBWI, BCSF, BHP, BIRD, BKNG, BMA, BMRN, CCRN, CDEV, CHDN, CHK, CLOV, CMLS, CPE, CSV, CTRA, CW, DHC, DK, DKL, EBAY, EFC, OTCPK:EIFZF, EVH, EXR, FBRT, FIVN, FIX, FLGT, FLS, FNF, FRG, FTI, FUBO, GBT, GH, G...

Apple (NASDAQ: AAPL) posts record revenue. Microsoft (NASDAQ: MSFT) makes its intentions clear with respect to its gaming division. Visa (NYSE: V) and American Express (NYSE: AXP) rise on strong results. Tesla (NASDAQ: TSLA) tells Wall Street not to e...

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it will relea...

Shares of companies that benefited from the pandemic have been crushed in the past few months. That's something shareholders of Fulgent Genetics (NASDAQ: FLGT) have gotten used to. The stock peaked early last year and has been yo-yoing ever since. The ups and downs have depe...

Fulgent has benefited tremendously from the COVID-19 pandemic tailwinds. But, its revenue could be set to decline following a highly successful two years. We believe that management needs to address its long-term operating model with more urgency in its FQ4 earnings call. None...

Shares of Fulgent Genetics (NASDAQ: FLGT) sank 36.5% amid turbulent trading for the broader market in January, according to data from S&P Global Market Intelligence . Both the S&P 500 and the Nasdaq Composite indexes entered into correction territory amid mountin...